4-Chloro-7-Tosyl-7H-Pyrrolo[2,3-d]pyrimidine CAS 479633-63-1 Purity >98.0% (HPLC) Tofacitinib Citrate Intermediate

Short Description:

4-Chloro-7-Tosyl-7H-Pyrrolo[2,3-d]pyrimidine

CAS: 479633-63-1

Purity: >98.0% (HPLC)

Appearance: White to Light Yellow Powder

Intermediate of Tofacitinib Citrate (CAS: 540737-29-9)

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

479633-63-1 - Description:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of 4-Chloro-7-Tosyl-7H-Pyrrolo[2,3-d]pyrimidine (CAS: 479633-63-1) with high quality, intermediate of Tofacitinib Citrate (CAS: 540737-29-9). Ruifu Chemical has been supplying pharmaceutical intermediates and APIs, fine chemicals more than 15 years. Ruifu Chemical can provide worldwide delivery, competitive price, excellent service.
Purchase Tofacitinib Citrate Intermediates or other products, please contact us by e-mail: alvin@ruifuchem.com

Intermediates of Tofacitinib Citrate:

Tofacitinib Citrate	CAS 540737-29-9
4-Chloropyrrolo[2,3-d]Pyrimidine	CAS 3680-69-1
4-Chloro-7-Tosyl-7H-Pyrrolo[2,3-d]Pyrimidine	CAS 479633-63-1
(3R,4R)-1-Benzyl-N,4-Dimethylpiperidin-3-Amine Dihydrochloride	CAS 1062580-52-2
(3R,4R)-1-Benzyl-N,4-Dimethylpiperidin-3-Amine	CAS 477600-70-7
2,4-Dichloro-7H-Pyrrolo[2,3-d]Pyrimidine	CAS 90213-66-4
(2R,3R)-2,3-Bis[(4-methylbenzoyl)oxy]butanedioic acid compd. with (3R,4R)-N,4-dimethyl-1-(phenylmethyl)-3-piperidinamine	CAS: 477600-71-8

479633-63-1 - Chemical Properties:

Chemical Name	4-Chloro-7-Tosyl-7H-Pyrrolo[2,3-d]pyrimidine
Synonyms	4-Chloro-7-Tosyl-7H-Pyrrolo[2,3-δ]pyrimidine; 4-Chloro-7-(p-Toluenesulfonyl)-7H-Pyrrolo[2,3-d]pyrimidine; 4-Chloro-7-(p-Toluenesulfonyl)-7H-Pyrrolo[2,3-δ]pyrimidine; 4-Chloro-7-[(4-Methylbenzene)sulfonyl]-7H-Pyrrolo[2,3-d]pyrimidine; Tofacitinib Impurity R
Stock Status	In Stock, Commercial Production
CAS Number	479633-63-1
Molecular Formula	C13H10ClN3O2S
Molecular Weight	307.75 g/mol
Melting Point	145.0 to 155.0℃
Density	1.49 g/cm3
Storage Temperature	Store Long-Term at 2-8℃
Shipping Conditions	Ambient
COA & MSDS	Available
Origin of Product	Shanghai, China
Product Categories	Pharmaceutical Intermediates
Brand	Ruifu Chemical

479633-63-1 - Specifications:

Items	Specifications	Results
Appearance	White to Light Yellow Powder	Off-White Powder
1H NMR Spectrum	Conforms to Structure	Conforms
Purity / Analysis Method	>98.0% (HPLC Area)	99.9%
Identified Impurity 1	≤0.20% (HPLC Area)	0.004%
Identified Impurity 2	≤0.15% (HPLC Area)	0.009%
Identified Impurity 3	≤1.50% (HPLC Area)	0.10%
Total Impurities	≤2.00% (HPLC Area)	0.14%
Any Unspecified Impurity	≤0.20% (HPLC Area)	0.03%
Melting Point	145.0~155.0℃	150.0~151.0℃
Loss on Drying	<2.00%	0.22%
Water by Karl Fischer	<1.00%	0.09%
Residue on Ignition	<0.50%	0.16%
Ni Metal Residue	<60ppm (Calculated on Dried Basis)	0.05ppm
Conclusion	The product has been tested and complies with the given specifications
Application	Intermediate of Tofacitinib Citrate (CAS: 540737-29-9)

479633-63-1 - Package/Storage/Shipping:

Package: Fluorinated bottle, Aluminium foil bag, 25kg/cardboard drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry (2~8℃), well-ventilated warehouse away from incompatible substances. Keep away from sunshine; avoid fire and heat sources; avoid moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.

479633-63-1 - Advantages:

Sufficient Capacity: Sufficient facilities and technicians

Professional Service: One stop purchasing service

OEM Package: Custom package and label available

Fast Delivery: If within stock, three days delivery guaranteed

Stable Supply: Maintain reasonable stock

Technical Support: Technology solution available

Custom Synthesis Service: Ranged from grams to kilos

High Quality: Established a complete quality assurance system

479633-63-1 - FAQ:

How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com

15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.

Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.

Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.

Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.

Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.

Factory Audit? Factory audit welcome. Please make an appointment in advance.

MOQ? No MOQ. Small order is acceptable.

Delivery Time? If within stock, three days delivery guaranteed.

Transportation? By Express (FedEx, DHL), by Air, by Sea.

Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.

Custom Synthesis? Can provide custom synthesis services to best fit your research needs.

Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.

479633-63-1 - Risk and Safety:

Hazard Symbols	Xn - Harmful
Risk Codes	22 - Harmful if swallowed
Hazard Class	IRRITANT
HS Code	2933599099

479633-63-1 - Application:

4-Chloro-7-Tosyl-7H-Pyrrolo[2,3-d]pyrimidine (CAS: 479633-63-1), is an important intermediate in the synthesis of Tofacitinib Citrate (CAS: 540737-29-9).
Tofacitinib Citrate, is a king of drugs developed by the US pharmaceutical company Pfizer for treating rheumatoid arthritis, trade name Xeljanz, for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid arthritis (RA) in adult patients. This product is a Janus kinase inhibitor, administered twice daily.
November 6, 2012, the US Food and Drug Administration (FDA) and Pfizer jointly announced Tofacitinib Citrate is approved for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid joints arthritis (RA) in adult patients.